Tarceva^© is a HER1/EGFR tyrosine kinase inhibitor with proven safety and tolerability

With a unique mechanism of action different from conventional chemotherapies, Tarceva^© was proven effective in diverse patient populations. ^[1,3,4]

Second-line treatment with Tarceva^© offered patients a proven survival advantage and an established tolerability profile combined with the ease of oral administration. ^[1,3]

In the second-line treatment of NSCLC, Tarceva^© can help prolong your patient's lifeline. ^[1,3]

REFERENCES
1. Tarceva^© (erlotinib) summary of product characteristics, F. Hoffmann-La Roche Ltd., 2007.
2. Shepherd FA, Pereira JR, Ciuleanu T, et al, for the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med. 2005;353:123-132.
3. Data on file, OSI Pharmaceuticals, Inc.
4. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11:689-708.